Alpine Associates Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Alpine Associates Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,028,400	Closed	-$77.4M	–	56
2022 Q2	$77.4M	Buy	+1,028,400	New	+$45.7M	2.91%	13

Alpine Associates Management's TPTX Position: Q3 2022 in Review

Alpine Associates Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,028,400 shares — an estimated $77.4M sold.

Alpine Associates Management first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $77.4M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Alpine Associates Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Alpine Associates Management sold 1,028,400 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $77.4M.
Alpine Associates Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Alpine Associates Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $77.4M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Alpine Associates Management's 13F filing for Q3 2022, filed 10 Nov 2022.